Brexit has made it more difficult for patients to receive life-changing drugs and treatments, DAUK committee members warned.
Speaking in the i Paper, Dr David Nicholl said drug companies were moving medical trials out of the UK.
Instead, they were being conducted in the EU and the US due to larger population sizes, he said.
Dr Nicholl said: “When the UK made a choice to leave the European Union, we made a choice to make it more difficult to carry out clinical trials.”
Dr Matt Kneale, former DAUK co-chair, said Brexit had made it tougher for NHS patients to access to new treatments.
Contributing to the same article, Dr Kneale said: “This is no longer just a policy debate, it’s about people’s lives – and right now patients in the UK are being let down.”
Please support our work by contributing to our crowd funder or by becoming a member.
